Impacted by their good diagnostic properties in RYR1 mutation-associated myopathies, a hypothesis was proposed that MYH1, ATP2A1, TNNT3, and MYLPF are likely to serve as biomarkers for diagnosing RYR1 mutation-associated myopathies. Here, MYL11 is linked to myopathy.